SEC Form 4 · accession 0001140361-15-023153
Skye Bioscience, Inc. · SKYE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas S Ingram
Officer — Vice Chairman · Director
Period of report
Jun 1, 2015
Accepted (ET)
Jun 3, 2015 · 7:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516551
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.00 | Jun 1, 2015 | A | 40,000 | A | — | Jun 1, 2025 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1Reporting Person's right to receive Stock Options vest over a five year period, with the first 20% of the total Stock Options vesting on the one year anniversary of the grant date and the remainder of the shares will vest in equal installments on a annual basis thereafter, such that the Stock Options are fully vested on June 1, 2020.